Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 6, 2021
(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction
of Incorporation)
File Number)
(IRS Employer
Identification No.)
5959 Horton Street, Suite 500, Emeryville, California
(Address of Principal Executive Offices)(Zip Code)
Registrant’s telephone number, including area code: (510550-8300
(Former Name or Former Address, if Changed Since Last Report.)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, par value $0.001 per shareZGNXThe Nasdaq Global Market
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02    Results of Operations and Financial Condition.

On May 6, 2021, Zogenix, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2021. A copy of this press release is attached hereto as Exhibit 99.1.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01    Financial Statements and Exhibits.

(d) Exhibits.
Exhibit Description

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 6, 2021By:/s/ Michael P. Smith
Name:Michael P. Smith
Title:Executive Vice President, Chief Financial Officer and Treasurer

EX-99.1 2 a2021q1erex-991.htm EX-99.1 Document
Exhibit 99.1
Zogenix Provides Corporate Update and Reports First Quarter 2021 Financial Results
Continued positive momentum for U.S. launch of FINTEPLA® (fenfluramine) oral solution in Dravet syndrome, with total net product sales of $12.3 million and total revenue of $13.7 million in the first quarter, representing quarter-over-quarter increases of 53% and 61%, respectively
As of March 31, 2021, in the U.S., over 700 patients referred to the FINTEPLA REMS program, with over 560 patients receiving reimbursed therapy
Successfully launched FINTEPLA in Germany in February and commenced the Zogenix Access Program to expand global access to FINTEPLA, including in European countries where reimbursement has not yet been established
On track to submit applications for FINTEPLA in Lennox-Gastaut syndrome in the U.S. in Q3 2021 and in Europe in Q4 2021
Planned New Drug Application (NDA) submission in first half of 2022 for MT1621 in TK2 deficiency
Intend to meet with FDA in current quarter to discuss Phase 3 study of FINTEPLA for the treatment of seizures associated with CDKL5 Deficiency Disorder (CDD)
EMERYVILLE, Calif., – May 6, 2021 – Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced financial results for the three months ended March 31, 2021, and provided a corporate update. The Company will host a conference call today, Thursday, May 6, at 4:30 PM Eastern Time/1:30 PM Pacific Time.
“We are pleased with the continued positive momentum in our U.S. launch of FINTEPLA® in Dravet Syndrome, where we see increased adoption by existing and new prescribers and patients,” said Stephen J. Farr, Ph.D., President and CEO of Zogenix. “Our dialogue with U.S. payors is progressing very well, as we work to expand access for patients who could benefit from FINTEPLA treatment. In Europe, our initial launch in Germany has begun in an encouragingly strong manner and our recently established Zogenix Access Program will expand access to FINTEPLA for physicians globally, including in European countries where reimbursement has not yet been established. Additionally, we are working to submit an NDA in Japan for FINTEPLA in the second half of this year.”
“We have the opportunity to potentially make FINTEPLA available to additional patients in need in multiple additional indications, and remain on track to submit global regulatory filings in Lennox-Gastaut syndrome (LGS) later this year and anticipate meeting with the FDA this quarter to discuss the planned Phase 3 trial for CDKL5 deficiency disorder,” continued Dr. Farr. “Lastly, in our MT1621 program for TK2 deficiency, we continue to prepare for an NDA filing in the first half of 2022.”
Corporate Update
FINTEPLA for the treatment of seizures associated with Dravet syndrome:
As of March 31, 2021, approximately 570 prescribers in the U.S. had successfully completed the Risk Evaluation and Mitigation Strategy (REMS) certification process

As of March 31, 2021, over 700 patients in the U.S. had been referred to the FINTEPLA REMS program to become eligible to receive therapy, and over 560 patients were receiving reimbursed therapy.
Received European Commission approval in December 2020; FINTEPLA commercially available in Germany as of February 1, 2021
Received temporary authorization to use FINTEPLA in France from the French National Agency for Medicines and Health Products Safety in January 2021; currently onboarding patients
Continued to advance reimbursement and pricing discussions with other major European countries, including the UK, Italy and France
Launched Zogenix Access Program to expand access to FINTEPLA for physicians in other parts of the world, where local regulations allow, including European countries where reimbursement has not yet been established
Anticipate submission of an NDA in Japan (J-NDA) to Japan’s Pharmaceutical and Medical Devices Agency in the second half of 2021
Presented new data from an investigator-initiated study of FINTEPLA in Dravet syndrome at American Academy of Neurology (AAN) Annual Meeting in April 2021, which highlighted certain quality-of-life benefits for patients and caregivers after patients received treatment with FINTEPLA
In March, two additional issued patents were listed in the Orange Book , bringing the total number of Orange Book listed patents for FINTEPLA to 10.
FINTEPLA for the treatment of seizures associated with LGS:
Compilation of data package is ongoing with anticipated submission of supplemental NDA in the third quarter of 2021
Anticipate submitting Marketing Authorization Application with European Medicines Agency in fourth quarter of 2021
Presented new data for FINTEPLA in LGS at AAN Annual Meeting, demonstrating that patients treated with FINTEPLA showed improvements in everyday executive function
FINTEPLA for the treatment of seizures associated with CDKL5 Deficiency Disorder:
Anticipate meeting with U.S. Food and Drug Administration (FDA) in the second quarter of 2021 to discuss plans for upcoming Phase 3 safety and efficacy study
Expect to initiate a Phase 3 study of FINTEPLA for the treatment of CDKL5 Deficiency Disorder during the second half of 2021
MT1621 for the treatment of TK2 deficiency:
Studies continue to proceed as planned and Company anticipates the submission of an NDA in the first half of 2022
First Quarter 2021 Financial Results
The Company recorded $13.7 million in revenue for the first quarter ended March 31, 2021, which was an increase of 61% as compared to the $8.5 million recorded in the fourth quarter of 2020. This included total net product sales of FINTEPLA of $12.3 million, which were an increase of 53% as compared to the $8.1 million reported in the fourth quarter of 2020, in

addition to $1.3 million in collaboration revenue as a result of the March 2019 collaboration with Nippon Shinyaku Co., Ltd. for FINTEPLA in Dravet syndrome and LGS in Japan. Zogenix recorded total revenue of $1.2 million for the three months ended March 31, 2020, which consisted solely of collaboration revenue.
Research and development expenses for the first quarter ended March 31, 2021, totaled $31.0 million, compared to $33.2 million in the first quarter ended March 31, 2020.
Selling, general and administrative expenses for the first quarter ended March 31, 2021, totaled $ 31.3 million, up from $21.3 million in the first quarter ended March 31, 2020. The increase was driven by the commercial launch of FINTEPLA in the U.S. and launch preparations in Europe.
Net loss for the first quarter ended March 31, 2021, was $55.6 million, or a net loss of $1.00 per share, compared with a net loss of $25.8 million, or a net loss of $0.54 per share, in the first quarter ended March 31, 2020.
As of March 31, 2021, the Company had $435.2 million in cash, cash equivalents, and marketable securities, compared to $505.1 million at December 31, 2020.

Conference Call Details
Thursday, May 6, at 4:30 PM Eastern Time / 1:30 PM Pacific Time
Toll Free:    877-846-2690
International:    416-981-9029
Conference ID:    21993693
Webcast:    http://public.viavid.com/index.php?id=144590
About Zogenix
Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company’s first rare disease therapy, FINTEPLA® (fenfluramine) oral solution, has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs, one in a rare epilepsy called Lennox-Gastaut syndrome and one in a mitochondrial disease called TK2 deficiency. Zogenix plans to initiate a study of FINTEPLA in a genetic epilepsy called CDKL5 Deficiency Disorder (CDD) and is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.
Forward-Looking Statements
Zogenix cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed,” and similar expressions are intended to identify forward-looking statements. These statements include: the timing of commercial launch of FINTEPLA for the treatment of Dravet syndrome in additional countries in Europe; Zogenix’s expectations on the submission of a J-NDA by Nippon Shinyaku in Japan; the timing and ability of Zogenix to complete regulatory submissions in the U.S. and the European for FINTEPLA in LGS; Zogenix’s plans to expand FINTEPLA in other indications including the timing or success of a Phase 3 clinical trial in CDD and investigator-initiated clinical trials in other indications; and Zogenix’s expectations regarding meeting with the FDA to discuss FINTEPLA in CDD. These statements are based on Zogenix’s current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Zogenix that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix’s business, including, without limitation: Zogenix may not be successful in executing its sales and marketing strategy for the commercialization of FINTEPLA in the U.S. and Europe, including due to the costs and procedures related to the REMS certification process or controlled access program; the COVID-19 pandemic may disrupt Zogenix’s business operations, impairing the ability to commercialize FINTEPLA and may delay Zogenix’s development plans for FINTEPLA and MT1621; unexpected adverse side effects or inadequate therapeutic efficacy of FINTEPLA or MT1621 that could limit development or commercialization, or that could result in recalls or product liability claims; additional data from Zogenix’s ongoing studies may contradict or undermine the data previously reported; patient outcomes may differ from the data previously reported and other risks described in Zogenix’s prior press releases as well as in public periodic filings with the U.S. Securities & Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Zogenix undertakes no obligation to revise or update this press release to reflect events or

circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
Melinda Baker
Senior Director, Corporate Communications
+1 (510) 788-8732 | corpcomms@zogenix.com

Brian Ritchie
Managing Director, LifeSci Advisors LLC
+1 (212) 915-2578 | britchie@lifesciadvisors.com

Stefanie Tuck
Vice President, Porter Novelli
+1 (978) 390-1394 | stefanie.tuck@porternovelli.com

(in thousands)
March 31, 2021December 31, 2020
Current assets:
Cash and cash equivalents$86,317 $166,916 
Marketable securities348,905 338,193 
Accounts receivable, net6,119 3,824 
Inventory2,324 1,026 
Prepaid expenses and other current assets11,065 12,215 
Total current assets454,730 522,174 
Property and equipment, net8,377 8,724 
Operating lease right-of-use assets7,452 7,748 
Intangible asset, net96,587 98,558 
Goodwill6,234 6,234 
Other non-current assets7,584 7,692 
Total assets$580,964 $651,130 
Current liabilities:
Accounts payable$11,964 $11,945 
Accrued and other current liabilities30,749 54,964 
Deferred revenue, current5,297 5,318 
Current portion of operating lease liabilities1,621 1,688 
Current portion of contingent consideration8,900 8,800 
Total current liabilities58,531 82,715 
Deferred revenue, noncurrent5,664 5,479 
Operating lease liabilities, net of current portion9,937 10,314 
Contingent consideration, net of current portion34,100 33,600 
Convertible senior notes151,451 149,353 
Total liabilities259,683 281,461 
Commitments and contingencies
Stockholders’ equity:
Common stock and additional paid-in capital1,701,788 1,694,580 
Accumulated deficit(1,380,470)(1,324,840)
Accumulated other comprehensive loss(37)(71)
Total stockholders’ equity321,281 369,669 
Total liabilities and stockholders’ equity$580,964 $651,130 

(In thousands, except per share amounts)
Three Months Ended March 31,
Net product sales$12,349 $— 
Collaboration revenue1,335 1,249 
Total revenues13,684 1,249 
Costs and expenses:
Cost of product sales (excluding amortization of intangible asset)676 — 
Research and development30,969 33,240 
Selling, general and administrative31,272 21,318 
Intangible asset amortization1,971 — 
Acquired in-process research and development costs— 1,500 
Change in fair value of contingent consideration600 (7,900)
Total costs and expenses65,488 48,158 
Loss from operations(51,804)(46,909)
Interest income308 1,088 
Interest expense(3,737)— 
Other (expense) income, net(397)20,021 
Net loss$(55,630)$(25,800)
Net loss per share, basic and diluted$(1.00)$(0.54)
Weighted average number of shares used in the calculation of basic and diluted net loss per common share55,750 48,185 

EX-101.SCH 3 zgnx-20210506.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 zgnx-20210506_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 zgnx-20210506_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 zgnx-20210506_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Written Communications Written Communications Pre-commencement Tender Offer Pre-commencement Tender Offer Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, City or Town Entity Address, City or Town Soliciting Material Soliciting Material Entity Address, Address Line One Entity Address, Address Line One Security Exchange Name Security Exchange Name Entity Address, Address Line Two Entity Address, Address Line Two City Area Code City Area Code Cover [Abstract] Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Central Index Key Entity Central Index Key Document Type Document Type Entity Emerging Growth Company Entity Emerging Growth Company Title of 12(b) Security Title of 12(b) Security Local Phone Number Local Phone Number Entity Address, State or Province Entity Address, State or Province Amendment Flag Amendment Flag Entity Address, Postal Zip Code Entity Address, Postal Zip Code Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Trading Symbol Trading Symbol Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name EX-101.PRE 7 zgnx-20210506_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 zgnx-20210506_htm.xml IDEA: XBRL DOCUMENT 0001375151 2021-05-06 2021-05-06 2021-05-06 0001375151 false 8-K 2021-05-06 ZOGENIX, INC. DE 001-34962 20-5300780 5959 Horton Street Suite 500 Emeryville CA 94608 510 550-8300 Common Stock, par value $0.001 per share ZGNX NASDAQ false false false false false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.1
May 06, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date May 06, 2021
Entity Registrant Name ZOGENIX, INC.
Entity Central Index Key 0001375151
Entity Incorporation, State or Country Code DE
Entity File Number 001-34962
Entity Tax Identification Number 20-5300780
Entity Address, Address Line One 5959 Horton Street
Entity Address, Address Line Two Suite 500
Entity Address, City or Town Emeryville
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94608
City Area Code 510
Local Phone Number 550-8300
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol ZGNX
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Sheet http://www.zogenix.com/role/Cover Cover Cover 1 false false All Reports Book All Reports zgnx-20210506.htm a2021q1erex-991.htm zgnx-20210506.xsd zgnx-20210506_cal.xml zgnx-20210506_def.xml zgnx-20210506_lab.xml zgnx-20210506_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "zgnx-20210506.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "zgnx-20210506_cal.xml" ] }, "definitionLink": { "local": [ "zgnx-20210506_def.xml" ] }, "inline": { "local": [ "zgnx-20210506.htm" ] }, "labelLink": { "local": [ "zgnx-20210506_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "zgnx-20210506_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "zgnx-20210506.xsd" ], "remote": [ "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "zgnx", "nsuri": "http://www.zogenix.com/20210506", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zgnx-20210506.htm", "contextRef": "ica94139f10ba4cadabe655cbd5b428e6_D20210506-20210506", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover", "role": "http://www.zogenix.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "zgnx-20210506.htm", "contextRef": "ica94139f10ba4cadabe655cbd5b428e6_D20210506-20210506", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.zogenix.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 17 0001375151-21-000044-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001375151-21-000044-xbrl.zip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�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end